252 results on '"Welters, Marij J P"'
Search Results
2. Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell carcinoma
3. CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors
4. The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer
5. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
6. T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation
7. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
8. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer
9. Actively personalized vaccination trial for newly diagnosed glioblastoma
10. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
11. HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia
12. Immunoguiding, the Final Frontier in the Immunotherapy of Cancer
13. The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer
14. Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer
15. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency
16. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
17. Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions
18. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry
19. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma
20. Guidelines for the automated evaluation of Elispot assays
21. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters
22. Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
23. Evaluation of Immunological Cross-Reactivity between Clade A9 High-Risk Human Papillomavirus Types on the Basis of E6-Specific CD4⁺ Memory T Cell Responses
24. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses
25. Detection of Adducts Formed upon Treatment of DNA with Cisplatin and Carboplatin
26. Association of Cervical Cancer with the Presence of CD4⁺ Regulatory T Cells Specific for Human Papillomavirus Antigens
27. Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival
28. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining
29. The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study
30. CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors
31. Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
32. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols
33. The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study
34. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future
35. PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
36. The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools
37. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions
38. Harmonization of the intracellular cytokine staining assay
39. CIMT 2010: Report on the eighth annual meeting of the association for cancer immunotherapy, May 26–28, 2010, Mainz, Germany
40. CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer: June 3–5, Mainz, Germany
41. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany
42. Report on the Fifth Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) April 12–14, 2007 in Würzburg, Germany
43. T-cell immune monitoring assays to guide the development of new cancer vaccines
44. Interferon‐γ and IL ‐5 associated cell‐mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa
45. Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers
46. The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
47. Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer
48. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
49. Actively personalized vaccination trial for newly diagnosed glioblastoma
50. EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.